Q32 Bio Inc. (Nasdaq: QTTB), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, announced on May 27, 2026 that it had entered into a securities purchase agreement to sell 6,725,000 shares of common stock at a price of $8.00 per share and pre-funded warrants to purchase 150,000 shares at a price of $7.9999 per pre-funded warrant, resulting in gross proceeds of approximately $55 million, excluding placement agent fees and other offering expenses. The private placement was led by BVF Partners L.P., with participation from RA Capital Management, OrbiMed, and Atlas Venture. The private placement closed on May 28, 2026.

WilmerHale represented the placement agents in the private placement.

The WilmerHale team was led by Lisa Firenze and Andrea Sorrentino and included Katharine Patterson and Whitley Horning.